87e4efe397430d655650e18a9d7619ee

NU ERA TIGHT 1 CH-SISTEMA TERAPÉUTICO BASADO EN ESTIMULACIÓN POR RADIOFRECUENCIA.

NU ERA TIGHT 1 CH-THERAPEUTIC SYSTEM BASED ON RADIOFREQUENCY STIMULATION.
REPRESENTACIONES OPTICAS COLOMBIANAS S.A - ROCOL S.A..·IIa·Colombia INVIMA·Expires April 29, 2031
Device classification
Risk class / Clase de Riesgo
IIa
Product type (Spanish)
MEDICO QUIRURGICOS
Product type (English)
SURGICAL DOCTOR
Registration information
Analysis ID
87e4efe397430d655650e18a9d7619ee
Expire date
April 29, 2031
Authorized company / Fabricante
Name (English)
REPRESENTACIONES OPTICAS COLOMBIANAS S.A - ROCOL S.A..
Product use / Uso del Producto
Spanish

"1- TRATAMIENTO DE DERMOPANICULOSIS EDEMATO-FIBRO ESCLERÓTICA; 2- TRATAMIENTO DE ATROFIA CUTÁNEA Y ELASTOSIS; 3- TRATAMIENTO DE MICROCIRCULACIÓN E INSUFICIENCIA VENOSA; 4-TRATAMIENTO DE HIPERPLASIA E HIPERTROFIA DE ADIPOCITOS. " _x000D_ _x000D_ _x000D_

English

"1- TREATMENT OF EDEMATO-FIBRO SCLEROTIC DERMOPANICULOSIS; 2- TREATMENT OF CUTANEOUS ATROPHY AND ELASTOSIS; 3- TREATMENT OF MICROCIRCULATION AND VENOUS INSUFFICIENCY; 4-TREATMENT OF HYPERPLASIA AND HYPERTROPHY OF ADIPOCYTES. " _x000D_ _x000D_ _x000D_

About this record

Access comprehensive regulatory information for NU ERA TIGHT 1 CH-SISTEMA TERAPÉUTICO BASADO EN ESTIMULACIÓN POR RADIOFRECUENCIA. (NU ERA TIGHT 1 CH-THERAPEUTIC SYSTEM BASED ON RADIOFREQUENCY STIMULATION.) in the Colombia medical device market through Pure Global AI's free database. This IIa medical device is registered under INVIMA analysis ID 87e4efe397430d655650e18a9d7619ee and manufactured by REPRESENTACIONES OPTICAS COLOMBIANAS S.A - ROCOL S.A... The device was registered on April 29, 2031.

This page provides complete registration details including product type (SURGICAL DOCTOR), authorised information, and regulatory compliance data from the official Colombia INVIMA medical device database. Pure Global AI offers free access to Colombia's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate INVIMA regulations efficiently.